Treat Obesity in Pets to Improve Liver Health

What we’ve long suspected is now official: the FDA just approved a weight-loss drug to treat liver disease.

On August 15, 2025, the US Food and Drug Administration (FDA) granted accelerated approval for semaglutide (Wegovy) to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis in adults (FDA, 2025). That decision does more than add another indication for a familiar drug. It reframes obesity therapy as liver therapy, raising a practical question for veterinary teams and the industry: if treating obesity improves liver outcomes in humans, how should we monitor and communicate liver outcomes in dogs and cats?